Fractyl Stock

fractyl.comHealthcare / BioTech & PharmaFounded: 2010Funding to Date: $286.48MM

Fractyl ais a biotechnology company looking to bring curative therapies to the large populations of patients with metabolic disease.

Register To Buy and Sell Shares

For more details on financing and valuation for Fractyl, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Fractyl’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Fractyl.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jay Caplan
President, Board Member & Co-Founder
Harith Rajagopalan Ph.D
Co-Founder, Chief Executive Officer and Board Member
Diane Marcou
Chief Financial Officer
Lisa Davidson
Chief Financial Officer
David Maggs
Chief Medical Officer

Board Members

Ajay Royan
Mithril Capital Management
Hemant Taneja
General Catalyst
William Bradley
Brian Dovey
Domain Associates
Christopher Gabrieli MD
Bessemer Venture Partners
Jay Caplan
Stanley Lapidus
Allan Will
Harith Rajagopalan Ph.D
John Amatruda

News Highlights

Fractyl Sets Out $99M IPO Ambitions After Busy Week of Biotechs Going Public
Fractyl Health, a biotechnology startup that focuses on preventing and curing metabolic diseases, announced in December 2023 that an initial public offering (IPO) may happen for the company. The company is sticking to that plan by selling 7.3 million shares for $14 to $16 each to add $99 million in capital. Fractyl Health has tested its Rejuva gene therapy candidate, which is a treatment that may compete with semaglutide drug Wegovy from pharmaceutical researcher Novo Nordisk.
Fractyl Health Aims For $100 Million IPO Raise
Fractyl Health, which is a startup that designs medical therapies for metabolic health, filed with the SEC to raise $100 million through an initial public offering (IPO). Specifically, the Lexington, Massachusetts-based company is working to treat Type 2 Diabetes as well as obesity in patients, and Fractyl Health will use the IPO capital to complete its Revitalize-1 research, fund the Remain-1 study and development of Rejuva gene therapy candidates, and prepare for commercialization of its therapies.
Fractyl Completes $44M Series D Financing |FinSMEs
Fractyl Laboratories Inc., a Lexington, Mass.-based developer of minimally invasive procedural therapy that can reverse metabolic diseases, completed a $44m Series D financing. The round was led by an undisclosed new investor, joined by new investors GV, True Ventures, and the IDO Fund and returning investors General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital …
Updated on: Apr 19, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.